Mortality, Cost, and Downstream Disease of Total Hip Medicare Population

被引：21

作者：

Lovald, Scott T. ^{[1
]}

Ong, Kevin L. ^{[2
]}

Lau, Edmund C. ^{[1
]}

Schmier, Jordana K. ^{[3
]}

Bozic, Kevin J. ^{[4
]}

Kurtz, Steve M. ^{[2
]}

机构：

[1] Exponent Inc, Menlo Pk, CA 94025 USA

[2] Exponent Inc, Philadelphia, PA USA

[3] Exponent Inc, Alexandria, VA USA

[4] Univ Calif San Francisco, Dept Orthopaed Surg, San Francisco, CA USA

来源：

JOURNAL OF ARTHROPLASTY | 2014年 / 29卷 / 01期

关键词：

downstream disease; total hip arthroplasty; Medicare; mortality; TOTAL KNEE ARTHROPLASTY; QUALITY-OF-LIFE; PATIENT SURVIVAL; REPLACEMENT; EXPECTANCY; OSTEOARTHRITIS; COMPLICATIONS; MORBIDITY; DEATH;

D O I：

10.1016/j.arth.2013.04.031

中图分类号：

R826.8 [整形外科学]; R782.2 [口腔颌面部整形外科学]; R726.2 [小儿整形外科学]; R62 [整形外科学（修复外科学）];

学科分类号：

100224 [整形外科学];

摘要：

The purpose of this study is to compare the differences in downstream cost and health outcomes between Medicare hip OA patients who undergo total hip arthroplasty (THA) and those who do not. All OA patients in the Medicare 5% sample (1998-2009) were separated into non-THA and THA groups. Differences in costs and risk ratios for mortality and new disease diagnoses were adjusted using logistic regression for age, sex, race, socioeconomic status, region, and Charlson score. Mortality, heart failure, depression, and diabetes were all reduced in the THA group, though there was an increased risk for atherosclerosis in the short term. The potential for selection bias was investigated with two separate propensity score analyses. This study demonstrates the potential benefit of THA in reducing mortality and improving aspects of overall health in OA patients. (C) 2014 Elsevier Inc. All rights reserved.

引用

页码：242 / 246

页数：5

共 30 条

[1]

In hospital cost of total hip arthroplasty in Canada and the United States [J].